Fate Therapeutics to Present at Upcoming Investor Conferences
November 04 2022 - 4:01PM
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”)
(NASDAQ: FATE), a clinical-stage biopharmaceutical company
dedicated to the development of programmed cellular immunotherapies
for patients with cancer, today announced that the Company will
present at the following upcoming investor conferences:
- Cowen’s 6th Annual IO Next Summit available on demand on
Friday, November 11, 2022 at 2:10 PM ET
- Jefferies London Healthcare Conference on Wednesday, November
16, 2022 at 12:55 PM GMT, 7:55 AM ET, in London, United
Kingdom
- Piper Sandler 34th Annual Healthcare Conference on Tuesday,
November 29, 2022 at 12:00 PM ET in New York, New York
A live webcast, if recorded, of each presentation can be
accessed under “Events & Presentations” in the Investors
section of the Company’s website at www.fatetherapeutics.com. The
archived webcast will be available on the Company’s website shortly
after the event.
About Fate Therapeutics, Inc.Fate Therapeutics
is a clinical-stage biopharmaceutical company dedicated to the
development of first-in-class cellular immunotherapies for patients
with cancer. The Company has established a leadership position in
the clinical development and manufacture of universal,
off-the-shelf cell products using its proprietary induced
pluripotent stem cell (iPSC) product platform. The Company’s
immuno-oncology pipeline includes off-the-shelf, iPSC-derived
natural killer (NK) cell and T-cell product candidates, which are
designed to synergize with well-established cancer therapies,
including immune checkpoint inhibitors and monoclonal antibodies,
and to target tumor-associated antigens using chimeric antigen
receptors (CARs). Fate Therapeutics is headquartered in San Diego,
CA. For more information, please visit
www.fatetherapeutics.com.
Contact:Christina TartagliaStern Investor
Relations, Inc.212.362.1200christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2023 to Apr 2024